We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

The donut hole was a gap in Medicare Part D prescription drug coverage that occurred between the initial stage and catastrophic stage of coverage. In 2025, new rules under the Inflation Reduction ...

It had various effects on Medicare, such as improving coverage and eliminating the drug coverage gap (also called the donut hole). More than 68 million people in the United States are enrolled in ...

Medicare has undergone several major changes since it launched in 1965. And now, with the passage of the Inflation Reduction Act of 2022, it's poised to change again, with several key ...

According to CMS data, Medicare Part D spending on Ozempic was more than $4.6 billion in 2022. Ozempic has become emblematic of the explosive enthusiasm for GLP-1 medications in the U.S. Danish ...

In one of its last actions, the Biden administration released the next 15 drugs selected for Medicare negotiation and the blockbuster diabetes drug Ozempic will be among those bargained for this year.

Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet selected for price negotiation, according to a report released Thursday.

WASHINGTON -- Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug ...

Medicare added Novo Nordisk's Ozempic, Wegovy, and Rybelsus to its 2027 drug price negotiations list. This move could force Novo Nordisk to slash the costs of its top drugs. The company should ...